RCKT Stock Summary and Trading Ideas (Rocket Pharmaceuticals | NASDAQ:RCKT)

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Rocket Pharmaceuticals trades on the NASDAQ stock market under the symbol RCKT.

As of October 2, 2026, RCKT stock price declined to $2.56 with 1,725,898 million shares trading.

RCKT has a beta of 2.32, meaning it tends to be more sensitive to market movements. RCKT has a correlation of 0.15 to the broad based SPY ETF.

RCKT has a market cap of $281.02 million. This is considered a Small Cap stock.

Last quarter Rocket Pharmaceuticals reported $0 in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-13 million and missed earnings estimates by -$.71.

In the last 3 years, RCKT traded as high as $32.53 and as low as $2.19.

The top ETF exchange traded funds that RCKT belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWN.

RCKT has underperformed the market in the last year with a price return of -20.2% while the SPY ETF gained +16.1%. RCKT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -33.3% and -24.0%, respectively, while the SPY returned +3.6% and +1.0%, respectively.

RCKT support price is $2.46 and resistance is $2.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCKT shares will trade within this expected range on the day.